BiotechTube

AP-PA02

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-cystic Fibrosis Bronchiectasis

Conditions

Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection

Trial Timeline

Jan 10, 2023 → Aug 8, 2024

NCT ID
NCT05616221

About AP-PA02

AP-PA02 is a phase 2 stage product being developed by Armata Pharmaceuticals for Non-cystic Fibrosis Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05616221. Target conditions include Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection.

What happened to similar drugs?

0 of 3 similar drugs in Non-cystic Fibrosis Bronchiectasis were approved

Approved (0) Terminated (1) Active (2)
❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
🔄Brensocatib 10 mg + Brensocatib 25 mg + PlaceboInsmedPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05616221Phase 2Completed
NCT04596319Phase 1/2Completed

Competing Products

8 competing products in Non-cystic Fibrosis Bronchiectasis

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
TIP + TIP and placebo + PlaceboNovartisPhase 2
35
CSL787 + PlaceboCSLPhase 2
42
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
47
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
35
Brensocatib 10 mg + Brensocatib 25 mg + PlaceboInsmedPhase 2
32
BrensocatibInsmedPre-clinical
23
Brensocatib 10 mg + Brensocatib 25 mg + PlaceboInsmedPhase 3
37